Intraocular pressure (IOP)-lowering eye drops can prevent glaucoma progression and hence preserve vision, but adherence may be inadequate in as many as 59 % of patients. Improving medication adherence is crucial for effective glaucoma control and represents a major challenge for physicians. Poor adherence, adverse events, poor health literacy and dissatisfaction with treatment are interrelated as well as being important risk factors for disease progression. Some adverse events may also reflect irreversible ocular damage with serious long-term consequences, including worsened outcomes following filtration surgery. Current treatment guidelines call for interventions that can maintain visual function and quality of life at a sustainable cost, including non-financial costs such as inconvenience and adverse events. Accumulating evidence suggests that the choice of first-line therapy is a leading determinant of long-term outcomes and economic costs. Effective early treatment that prevents or delays glaucoma progression could halve the long-term costs of disease management. Selecting an effective and well-tolerated IOP-lowering formulation is thus a vital first step to achieving effective disease control for the patient's lifetime. A holistic approach to patient management should comprise a straightforward regimen including effective and well-tolerated drugs (and excipients), combined with patient-centred communication to optimise disease understanding. Available data suggest that addressing all known causes of non-adherence from the start may prove to be the best strategy for managing glaucoma. Ongoing research offers potential drug delivery technologies that could increase patient adherence while improving efficacy and decreasing adverse effects and, ultimately, maintaining vision for glaucoma patients. Until these innovations are introduced, we can only choose the best options currently available.
Medication can preserve visual function long term, but poor adherence is a major issue affecting around 22-59 % of patients. [4] [5] [6] Barriers to adherence fall into four main categories:
• situational/environmental factors, such as travel or variation in routine;
• medication regimen, such as adverse effects or complexity;
• patient factors, such as skill in application and memory; and
• provider factors, such as communication and satisfaction with care. 7 Physicians can influence adherence strongly via two of these categories: medication regimen and provider factors.
There is a shift away from a goal of maximum efficacy in glaucoma management -that is, achieving the strongest IOP reduction possible -and towards optimal effectiveness -that is, sufficient IOP reduction to preserve visual function while minimising adverse effects, inconvenience and economic costs. 8 This more pragmatic approach acknowledges the impact of adverse effects and adherence on efficacy and offers an opportunity to improve outcomes without increasing costs.
This article reviews the influence of factors such as adverse effects on adherence and how this affects efficacy and hence glaucoma progression, before discussing how clinicians can apply their growing understanding of these factors to optimise patient outcomes in a cost-effective way.
Adherence is uniformly a problem in glaucoma since the disease is asymptomatic until the very late stages, and because treatment prevents further vision loss but does not result in any perceptible improvement in visual status. Thus, there is little positive feedback to encourage adherence, and issues such as adverse effects, difficulty administering eye-drop medications and cost are also limiting factors for good adherence to treatment in most countries. A poly-drug regimen can also result in diminished effectiveness through the wash-out effect, in which multiple eye drops administered without proper spacing between them can lead to wash-out of earlier medications by later medications, before optimal ocular penetration has occurred.
The association between patient satisfaction and treatment compliance, or at least intention to or persistence in taking medications, has been documented. 10 Specifically, glaucoma patient satisfaction with treatment has been demonstrated to be a key driver of compliance. 11 In a representative sample of patients treated with an IOP-lowering therapy, some associations were found between burning and stinging, vision-related quality of life and compliance.
Patients with reported adverse events frequently missed instillation.
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The relative convenience and adverse effect profiles of therapies may be additional important factors in treatment decision making.
More complex medication dosing schedules have been shown to negatively impact adherence in glaucoma patients.
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Quantifying non-adherence, and assessing the contribution of different factors, can be problematic using conventional study designs. The prevalence of self-reported non-adherence to glaucoma medication is high (27.3 % according to a Dutch survey), 16 but may actually underestimate true non-adherence over time. 16, 17 Randomised controlled trials can achieve strong internal validity (an unbiased estimate of difference between groups); however, their external validity (applicability to everyday clinical practice) can be limited because enrolling onto a trial may influence patient behaviour. This is particularly relevant when assessing adherence, which is likely to improve when patients know that they are under observation.
Multiple obstacles to adherence have already been identified, including poor education, lack of motivation, forgetfulness, drop application and age differences. Motivation for adherence is also determined by fear of blindness and a faith in drop efficacy. 18 Non-adherence may also be attributable to poor eye-drop application technique by older patients. 19 We have developed a specific methodology both to assess medical outcomes over time and to identify factors that influence these outcomes. 20 An initial study recruited 127 representative patients with primary open-angle glaucoma (POAG), normal-tension glaucoma or ocular hypertension via a randomly selected list of ophthalmologists. 20 Disease progression, defined as a deterioration of optic nerve head and/or visual field within 2.5 years of initial diagnosis, occurred in 12 patients (9.5 %) during a mean follow-up of 2.4 years, but was not linked to any of the main clinical characteristics except time since diagnosis.
However, there were significant correlations between disease progression and adverse effects or dissatisfaction with treatment (see Figures 1 and 2) . 20 Disease progression was 3.3-fold higher in patients who experienced adverse events and 2.4-fold higher in patients who were dissatisfied with treatment. 20 The study also linked treatment changes to disease progression, with an 8.7-fold increase in progression after one change (22.6 %) and a 17.7-fold increase after multiple changes (46.2 %) compared with patients who stayed on the same treatment throughout the study follow-up (2.6 %). 20 Patients with disease progression appeared to have more changes in treatment and adverse events and they were also more likely to have complained about being unhappy with their treatment.
Role of Treatment Adverse Effects
Adverse effects of topical hypotensive therapy for glaucoma, such as conjunctival hyperaemia, discomfort and itching, are a leading cause of non-adherence. [21] [22] [23] Patients taking fewer doses than prescribed may be at risk of having worse outcomes than those taking a higher proportion. Adverse Effects, Adherence and Cost-Benefits in Glaucoma Treatment effects with PGAs compared with beta-blockers. 24 PGAs have a good systemic safety profile and the one-day dosing has the potential to simplify the topical regimen. Conjunctival hyperaemia is reported to be the most common adverse event in PGA-treated patients and appears to be dose-related, according to a recent randomised controlled trial comparing two doses of bimatoprost. 25 Discontinuation rates were 2.2 and 6.4 % in the bimatoprost 0.01 and 0.03 % groups, respectively. 25 Other treatment-related local adverse events include skin hyperpigmentation, eye irritation or pruritus, eyelash growth and eyelid erythema. 25 Some localised adverse effects of glaucoma therapy may reflect progressive and irreversible damage, such as subconjunctival fibrosis.
Long-term glaucoma treatment has been linked with cataracts, dry eye and impaired wound healing following filtration surgery. 26, 27 Trabeculectomy failure has been directly linked with topical glaucoma treatment and was significantly higher after more than 12 months of treatment, compared with a mean of two weeks (maximum eight weeks), of pre-operative treatment in a study of 81 patients. 28 Selecting the lowest effective dose of antiglaucoma agents may be important to limit the risk of ocular damage attributable to treatment-related adverse effects. However, evidence linking eye-drop preservatives with adverse effects has fuelled debate about whether the pharmaceutically active ingredients should be our primary concern.
Benzalkonium chloride (BAK) is commonly used as a preservative in multidose bottles of topical glaucoma medications. Numerous in vitro data linked BAK with a dose-dependent toxic effect on human conjunctival and corneal epithelial cells. 29 Cell survival fell with increasing BAK concentrations, whether BAK was delivered in an inert solution or combined with active glaucoma treatments, PGA and/or a beta-blocker, timolol. 29 These results are consistent with previous in vitro evidence that BAK induced major irreversible damage in human conjunctival cell lines. 30 Ophthalmologists should therefore already be considering the minimum dosage necessary to achieve therapeutic benefit, but also be monitoring closely for local and systemic adverse effects, 31 and the use of preservative-free formulations in subpopulations with abnormal tearing should be seriously considered. 32 Some of these symptoms may actually reflect progressive and partially reversible major ocular surface changes, including subconjunctival fibrosis, increasing the risk of failure of further glaucoma surgery.
All the components of the hypotensive eye drops, including the active ingredient, the pH, the preservatives and the excipients, may be involved in the occurrence of these adverse effects. It is thus important to identify the agents involved and the mechanisms of these adverse effects in order to select a therapy minimising their risk and the discomfort felt by patients, thereby increasing the likelihood of good compliance. Preservative-free solutions should be considered when available. 33, 34 Clinical research has also shown that adverse effects are significantly less common with preservative-free preparations compared with standard preservative-containing eye drops. 35, 36 Large-scale epidemiological studies have reported higher frequencies of all recorded symptoms and signs of irritation (palpebral, conjunctival and corneal) in patients using preservative-containing versus preservative-free preparations. 35, 36 A cross-sectional study including 9,658 patients in four European countries found that all symptoms were more than twice as common in the group using preservative-containing treatments:
48 versus 19 % had discomfort or pain during instillation; 48 versus 20 % reported stinging or burning; 42 versus 15 % experienced foreign body sensation; and 35 versus 16 % had dry eye sensation in preservative-exposed versus preservative-free groups, respectively. 35 A similar cross-sectional study in 4,107 patients revealed similar results, for example discomfort upon instillation in 43 versus 17 %. 36 Both studies also showed that eliminating or reducing preservative exposure dramatically reduced symptom frequency (see Figure 3) .
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Cost-effectiveness
A number of groups have attempted to map cost-effectiveness in a variety of glaucoma populations. As would be expected, the resource consumption associated with this chronic disease demonstrates greater medical effort as disease severity worsens. Increased medical effort is prompted by physicians in order to slow progression of the condition, but it is also driven by patient concerns. Glaucoma therapy is cost-effective compared with no treatment; however, simulation models are inconsistent regarding when to treat ocular hypertension and comparing different therapeutic interventions. 37 However, health policy involves the investment of public resources, Figure 4) . 45 The number of glaucoma medications (at least 42 % of direct costs, assuming full adherence) increased linearly from disease stage 0 to 5. 45 There was a linear rise in the number of ophthalmologist visits per person-year as disease stage worsened. 45 Survey data have also shown that patients may visit their ophthalmologist more often if they are dissatisfied with treatment, with 3.5 visits/year versus two. 27 visits/year for dissatisfied versus satisfied patients. 12 Traverso et al. More recent studies have identified treatment changes as a major contributor to rising costs. 42, 43 Danish registry data on 27,380 patients who began antiglaucoma therapy between 2002 and 2007 revealed that, after a mean 2.4-year follow-up, only 37 % were still using their original treatment regimen. 42 A further 21% had switched therapy once, while 43 % had experienced three or more treatment changes. 42 Medication accounted for 61 % of initial direct healthcare costs in this study, but fell to 51 % after three treatment changes while other costs increased. 42 Annual costs of ophthalmologist visits, for example, increased from an initial €110 to €239 in patients on their third or more treatment regimen. 42 Annual healthcare costs per patient were €305 during their first treatment regimen, rising to €744 after three treatment changes. 42 Another recent publication reported rising costs with medication changes, and concluded that effective and well-tolerated initial treatment was the most cost-effective approach to glaucoma management. 43 A 10-year Markov model based on the UK health system and populated with data from 93 studies revealed only small differences in rates of failure to control IOP for first-line monotherapy using different PGAs. 43 However, reduced hyperaemia led to prolonged treatment in one group and 10-year cumulative costs were lowest despite higher drug acquisition costs versus the alternative PGAs. 43 Drug costs accounted for just 8-13 % of total costs of glaucoma in this model, which included costs of outpatient visits, surgery and indirect costs of low vision, such as care for a blind or partially sighted patient. 43 A novel analysis of data for 1,816 patients, taken from the UK General Practitioner Research Database, also concluded that the most durable treatment sequence was the most cost-effective. 40 This analysis linked the most persistent treatment sequence with lower monthly costs of drugs, consultations and total monthly costs compared with alternative treatment sequences. 40 The most cost-effective treatment sequence started with a different first-line PGA to the above study, but the results were consistent in that they linked treatment persistence with cost savings.
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The first prospective study of long-term costs and outcomes of PGA treatment in clinical practice reported a four-year follow-up of 467 patients with POAG or ocular hypertension who were starting first-or second-line PGA treatment for insufficiently controlled IOP. 39 The results linked PGA therapy with very little progression over four years, and 52 % of patients remained on their initial treatment throughout the study. 39 There was no overall increase in treatment costs despite the relatively high acquisition costs of PGAs. The authors estimated that the costs of surgery and consultations had fallen by around 70 and 34 %, respectively, with increased use of PGAs. Both baseline IOP and treatment switches were linked to increased healthcare costs. 39 First-line PGA therapy appeared to be significantly more effective than initial treatment with a beta-blocker, providing more days of IOP control primarily owing to the longer time until initial treatment failure. 46 There is also evidence that, while screening of the general population may not be cost-effective, screening of at-risk groups including the elderly and those with a family history of glaucoma may be cost-effective. 38 Since models estimate that the lifetime cost of ocular hypertension is higher than that of glaucoma, with the social costs of each disease not being compared, first-line use of the most effective therapy would reduce medical and social costs. 41 , compared with no increase in the control group. 44 Repeat LTP appeared to be a major driver of increased costs following LTP: 507
Cost Implications of Laser Trabeculoplasty
Adverse Effects, Adherence and Cost-Benefits in Glaucoma Treatment There was a US$2,101 increase in ophthalmology-related non-pharmacy charges for patients who had a repeat LTP compared with US$773 in patients who did not require repeat LTP within one year after index LTP. 44 A Canadian study has also shown that selective LTP as primary therapy, at a per-patient level, offers a modest potential cost saving over primary medical therapy in the management of POAG.
47
Patient Management
The efficacy and cost-effectiveness of medical treatment rely on adequate adherence, but chronic adherence rates are likely to be poorer than either randomised controlled trial or survey data suggest.
It is probably best to assume low adherence in the clinic and apply management strategies that can optimise adherence. For example, selecting preservative-free medications may avoid poor adherence attributable to preservative-related adverse effects.
The physician's role goes beyond treatment selection and patient monitoring, however; education and counselling are particularly important to support patients with chronic conditions such as glaucoma. A cross-sectional study in 408 subjects highlighted the scope for improvement: misconceptions about the disease and its treatment were common in both newly diagnosed and established glaucoma patients. 48 For example, 36 % of established glaucoma patients believed that watery eyes indicated increased pressure inside the eye, 80 % were unaware that topical glaucoma treatments could have systemic adverse effects and 48 % thought that they would have symptoms warning them of disease progression. 48 Knowledge scores were highest for patients who had been referred to an optometrist, shared the same first language as their healthcare provider or received private treatment, which are all factors that could influence their health information and counselling. 48 Other evidence has linked poor disease understanding (or health literacy) with impaired treatment adherence and patient outcomes. 49, 50 Health literacy (Rapid Assessment of Adult Literacy in Medicine [REALM] score) was the only factor that predicted the number of medication refills requested over six months in a study of 197 patients with glaucoma. 50 There was no link between refill rates and age, gender, race or level of education in this study. 50 A cross-sectional study of 204 patients with established glaucoma also linked poor health literacy with both a lack of glaucoma education and worsened glaucoma outcomes (see Figure 5 ) 49 . Patients with poor health literacy had higher rates of missed appointments and missed eye drops (see Figure 5 ) 49 Glaucoma worsening was also increased in patients without glaucoma education. 49 There is evidence that supplementary education for physicians and patients can improve patients' disease understanding. 51, 52 In one study, Glaucoma Management Researchers are also exploring the potential for glaucoma drug delivery using injectable microspheres, which could replace daily self-administration with an injection every few months. [58] [59] [60] Another option under investigation is to deliver IOP-lowering drugs via hydrogel contact lenses. [61] [62] [63] [64] Preliminary evidence suggests that this is a feasible method of antiglaucoma drug delivery. 63 These novel technologies are designed to improve clinical efficacy by providing many delivery alternatives and can manage IOP for several months.
Another crucial unmet need in glaucoma management is the 
Conclusion
Public health decisions in glaucoma therapy should take a broad economic view incorporating the lifetime duration of the disease.
There remains a position within and outside the healthcare system for therapeutic innovations with important economic consequences that bring high added value to patients. 41 n Adverse Effects, Adherence and Cost-Benefits in Glaucoma Treatment
